Alzheimer's disease plasma biomarkers are differentially affected by Type II Diabetes Mellitus based on those with Alzheimer's disease

Abstract

Background: Type II Diabetes Mellitus (T2DM) remains one of the strongest comorbidities associated with the development of AD. Use of fluid‐based biomarker assays allows for quick, inexpensive, and accurate identification of those at high risk for developing AD or likely already have the disease.

The paper